Event will feature presentations from community opinion leaders and PharmaEssentia’s senior leadership team

PharmaEssentia USA Corporation (PEC USA), a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, announced that it will host an Investor Day on Wednesday, November 30, 2022, 8:00 - 10:30 a.m. ET, at Convene (101 Park Avenue) in New York City.

The event will include a detailed discussion on the impact of BESREMi (ropeginterferon alfa-2b-njft) in polycythemia vera (PV), its market opportunity and the Company's future-focused scientific strategy. In addition, key community leaders, including Srdan Verstovsek, M.D., Ph.D., MD Anderson Cancer Center and Ann Mullally, M.D., Brigham and Women’s Hospital / Dana-Farber Cancer Institute, will share their perspectives on the evolving treatment paradigm in PV and scientific momentum in comprehensive care for myeloproliferative neoplasms (MPN). Formal presentations will be followed by a Q&A session.

To attend the event in person or virtually, please click here for registration. A live webcast and replay of the event will be available on the PharmaEssentia USA website at https://us.pharmaessentia.com/.

If you have any questions, please contact Brandon Weiner at brandon.weiner@westwicke.com.

About PharmaEssentia

PharmaEssentia (TPEx: 6446), headquartered in Taipei, Taiwan, is a global and rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, PharmaEssentia aims to deliver effective new biologics for challenging diseases in the areas of hematology and oncology, with one approved product and a diversifying pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today PharmaEssentia is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung, Taiwan.

For more information about PEC USA, visit the website, LinkedIn or Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221121005040/en/